Circulating Tumor DNA for Prediction of Complete Pathological Response to Neoadjuvant Radiochemotherapy in Locally Advanced Rectal Cancer (NEORECT Trial).

MLA

Mögele, Tatiana, et al. “Circulating Tumor DNA for Prediction of Complete Pathological Response to Neoadjuvant Radiochemotherapy in Locally Advanced Rectal Cancer (NEORECT Trial).” Cancers, vol. 16, no. 24, Dec. 2024, p. 4173. EBSCOhost, https://doi.org/10.3390/cancers16244173.

APA

Mögele, T., Höck, M., Sommer, F., Friedrich, L., Sommer, S., Schmutz, M., Altenburger, A., Messmann, H., Anthuber, M., Kröncke, T., Stüben, G., Trepel, M., Märkl, B., Dintner, S., & Claus, R. (2024). Circulating Tumor DNA for Prediction of Complete Pathological Response to Neoadjuvant Radiochemotherapy in Locally Advanced Rectal Cancer (NEORECT Trial). Cancers, 16(24), 4173. https://doi.org/10.3390/cancers16244173

Chicago

Mögele, Tatiana, Michael Höck, Florian Sommer, Lena Friedrich, Sebastian Sommer, Maximilian Schmutz, Amadeus Altenburger, et al. 2024. “Circulating Tumor DNA for Prediction of Complete Pathological Response to Neoadjuvant Radiochemotherapy in Locally Advanced Rectal Cancer (NEORECT Trial).” Cancers 16 (24): 4173. doi:10.3390/cancers16244173.